Results 141 to 150 of about 362,523 (334)

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

The Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpia, Rita Chiari, Alberto Pavan, Alessandro Dal Maso, Valentina Da Ros, Giada Targato, Sabrina Vari, Stefano Indraccolo, Fiorella Calabrese, Stefano Frega, Laura Bonanno, Pier Franco Conte, Valentina Guarneri, Giulia Pasello   +21 more
wiley   +1 more source

RPSLearner: A Novel Approach Based on Random Projection and Deep Stacking Learning for Categorizing Non‐Small Cell Lung Cancer

Advanced Intelligent Systems, EarlyView.
Identifying non‐small cell lung cancer (NSCLC) subtypes is essential for precision cancer treatment. Conventional methods are laborious, or time‐consuming. To address these concerns, RPSLearner is proposed, which combines random projection and stacking ensemble learning for accurate NSCLC subtyping. RPSLearner outperforms state‐of‐the‐art approaches in
Xinchao Wu, Jieqiong Wang, Shibiao Wan
wiley   +1 more source

Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non‐Small Cell Lung Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background LIBRETTO‐001 is an ongoing, global, open‐label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient‐reported outcomes in patients with RET fusion–positive non‐small cell lung cancer (NSCLC).
Anna Minchom, Aaron C. Tan, Erminia Massarelli, Vivek Subbiah, Valentina Boni, Bruce Robinson, Lori J. Wirth, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Caroline E. McCoach   +11 more
wiley   +1 more source

Bioinformatics‐based discovery of the involvement of PSAT1 in mediating the anti‐lung adenocarcinoma activity of triptolide

Animal Models and Experimental Medicine, EarlyView.
Transcriptome sequencing was performed on tumor tissues from triptolide‐treated tumor‐bearing mice. The sequencing results were integrated with data from public databases for comprehensive analysis, and potential regulatory targets of triptolide were identified.
Zhiwen Cao, Lulu Zhang, Wenqiang Zhang, Rong Wan, Xiaogang Peng, Jinyan Xie, Ruru Bai, Jiejing Jin, Changqi Shi, Lan Yan, Xiangyu Guo, Yang Shen, Cheng Lu   +12 more
wiley   +1 more source

Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

British Journal of Clinical Pharmacology, EarlyView.
Aims In the AEGEAN study, perioperative durvalumab plus platinum‐based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non‐small‐cell lung cancer (NSCLC) demonstrated a favourable benefit–risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure–response (ER) relationships of durvalumab in patients ...
Xiaoying Zhao, Junjie Ding, Jiajia Zhao, Ling Zhang, Aburough Abegesah, Yu‐qian Zhang, Cathy O'Brien, Gary J. Doherty, Allen C. Chen, KyoungSoo Lim, Song Ren, Peiming Ma, Diansong Zhou   +12 more
wiley   +1 more source

C3-03: Randomized, phase III Study of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (TRT) for unresectable stage III non-small-cell lung cancer (NSCLC): WJTOG0105 [PDF]

, 2007
Kimihide Yoshida, Hisao Uejima, Miyako Satouchi, Shinzoh Kudoh, Kazuhiko Nakagawa, Toyoaki Hida, Masaaki Kawahara, T Sugiura, Kenji Tamura, Masahiro Fukuoka   +9 more
openalex   +1 more source

Health-related quality of life in KEYNOTE-010 : a phase II/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC

, 2019
Introduction: In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1-expressing (tumor proportion score
Ahn, Myung-Ju, Barlesi, Fabrice, de Castro, Gilberto, Jr., Deitz, Anne C., Felip, Enriqueta, Fidler, Mary Jo, Garon, Edward B., Gubens, Matthew A., Han, Ji-Youn, Herbst, Roy S., Kim, Dong-Wan, Kim, Joo-Hang, Li, Qiao, Lubiniecki, Gregory M., Surmont, Veerle   +14 more
core   +1 more source

Induction Chemotherapy using Carboplatin(C), Irinotecan(I), and Paclitaxel(P) with Pegfilgrastim Followed by Concurrent Conformal Radiation Therapy (CRT) with Weekly Carboplatin/Paclitaxel and Daily Gefitinib (Iressa) Followed by Maintenance Gefitinib for Patients with Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) [PDF]

, 2005
David E. Morris, Jan Halle, Thomas E. Stinchcombe, Julian Rosenman, Maureen Tynan, D. Neil Hayes, A. Mears, Mark A. Socinski   +7 more
openalex   +1 more source

Pan-squamous genomic profiling stratified by anatomic tumor site and viral association [PDF]

, 2018
Background: Squamous cell carcinomas (SCC) have diverse anatomic etiologies but may share common genomic biomarkers. We profiled 7,871 unique SCCs across nine anatomic sites to investigate commonality in genomic alterations (GA), tumor mutational burden (
Albacker, L. A., Ali, S. M., Chung, C. H., Frampton, G. M., Johnson, J. M., Kang, H., Khan, S. A., Miller, V. A., Montesion, M., Ross, J. S., Sokol, E. S.   +10 more
core   +1 more source

Mechanisms of Resistance to Cancer Immunotherapy: A Host–Tumor Interaction Perspective; A Review Article

Cancer Nexus, EarlyView.
Mechanisms of resistance to cancer immunotherapy from a host–tumor interaction perspective. The central tumor cell is protected by multiple resistance mechanisms, including genetic mutations, epigenetic modifications, and metabolic alterations. The immunosuppressive tumor microenvironment features myeloid‐derived suppressor cells (MDSCs), regulatory T ...
Mohammed Elmujtba Adam Essa, Hamid Noori, Abdelkareem A. Ahmed   +2 more
wiley   +1 more source